The iPS Cell market is a rapidly growing sector within the pharmaceutical industry. It is based on the use of induced pluripotent stem cells (iPSCs) to develop treatments for a variety of diseases. iPSCs are derived from adult cells, such as skin or blood cells, and are reprogrammed to become pluripotent stem cells. These cells can then be used to create a variety of cell types, such as neurons, heart cells, and liver cells, which can be used to study diseases and develop treatments. The iPS Cell market is driven by the increasing demand for personalized medicine, as well as the potential for iPSCs to be used in regenerative medicine. Additionally, the use of iPSCs in drug discovery and development is becoming increasingly popular, as it allows for the testing of drugs on human cells in a laboratory setting. Some of the major players in the iPS Cell market include Cellular Dynamics International, Takara Bio, ReproCELL, and Axol Bioscience. Additionally, a number of biotechnology companies, such as Novocell and Pluristem, are also developing iPSC-based treatments. Show Less Read more
ASK A QUESTION
We request your telephone number so we can contact you in the event we have difficulty reaching you via email. We aim to respond to all questions on the same business day.
